Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Payables (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Payables for 3 consecutive years, with $5.0 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Payables fell 93.54% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Sep 2024, down 93.54%, and an annual FY2023 reading of $51.6 million, up 1139.82% over the prior year.
  • Payables was $5.0 million for Q3 2024 at Oramed Pharmaceuticals, up from $3.5 million in the prior quarter.
  • Across five years, Payables topped out at $77.9 million in Q3 2023 and bottomed at $831000.0 in Q2 2023.
  • Average Payables over 3 years is $17.4 million, with a median of $4.2 million recorded in 2022.
  • The sharpest move saw Payables skyrocketed 1722.78% in 2023, then tumbled 93.54% in 2024.
  • Year by year, Payables stood at $4.2 million in 2022, then soared by 1139.82% to $51.6 million in 2023, then crashed by 90.25% to $5.0 million in 2024.
  • Business Quant data shows Payables for ORMP at $5.0 million in Q3 2024, $3.5 million in Q2 2024, and $33.3 million in Q1 2024.